Novel oral plasma kallikrein (PKa) inhibitors KV998052 and KV998054 ameliorate VEGF-induced retinal thickening in a murine model of retinal edema.

Murugesan N, Clermont AC, Pethen SJ, Li L, Duckworth EJ, Hampton SL, and Feener EP.